Funding for this research was provided by:
Shire Human Genetics Inc
Received: 22 September 2020
Accepted: 26 January 2021
First Online: 18 February 2021
Ethics approval and consent to participate
: The study protocol and study materials were reviewed and approved by Western Institutional Review Board (Puyallup, WA) prior to any recruitment and data collection activities. The survey was conducted in compliance with local regulations and guidelines as appropriate. Patients were required to give consent through the survey web link before completing the survey.
: Not applicable.
: JM is a full-time employee of Takeda Pharmaceuticals International AG and holds stocks/options in Takeda. RM and MDLC are full-time employees of ICON. EJ was a full-time employee of ICON at the time the study was conducted. HBB is a consultant for HAE International. GJ, IH, and GD are full-time employees of Takeda Pharmaceutical Company Limited and hold stocks/options in Takeda. EA-P has received honoraria, research funding, and/or travel grants from Adverum, BioCryst, CSL Behring, KalVista, Pharming, Pharvaris, and/or Takeda, and/or served as a consultant for these companies.